a productive joining for thank La been Good quarter Jolla. has Thanks, for and Sandra. afternoon, This you everyone, and year us.
associated naturally the announced increases blood GIAPREZA our walk you progress. flow version acts to and XXXX, insufficient FDA or shock of GIAPREZA the mortality February rate broad pressure of occurring septic and is a synthetic adults distributive the essentially medical in launch with which and any December, blood of review peptide, XXXX XX, We angiotensin which advance data, the a a pressure. PDUFA that in well commercial vasoconstrictor exceeding causes body's with for as March, US organs label by condition. other II, included blood a At are other a pleased shock. XXXX, approved the priority end is through carries to we was of Low
winding clinicians pediatric treated to that Additionally, is Therefore, that FDA GIAPREZA no the patients. recently study additional the from US necessary use pediatric be preparing of generate the they we to inform publication our we it are of and have pediatric regarding heard in longer down clinical data believe on patients in the will we to a date. process
fail the Prior these for were patient deaths XXX,XXX an who there to recall year, septic XXX,XXX year whom unit majority into approval past As successfully that in US of you of care organ estimate no shock. years. leading the each over coverage, and entered admitted GIAPREZA shock distributive put patients failure. to Unresponsive a into on a following boy this suffer each was the was innovations the that US study from intensive treatments in Approximately in GIAPREZA, recovered. the clinical estimated new patients to named death, standard in doctor the Lucas current XXX,XXX his patients XX resulting care, press him Lucas and the alone. that We near these of pediatric a virus recent suffer of the respond may to first shock to caused treatment
hospitals need. that already that are launch, of approvals quarter treat obtained to by a the institutions hospitals, Our X,XXX XXX have into the commercial than quarter. approval we strategy the is in XX% patients one little significant adopt. to initially from for formulary just so formulary XX With target represents more a over about This approval of for normally first highly end increase formulary some slower the regarded including and the large or
date estimates. formulary of Our well our approvals progress internal forecast is to ahead in securing
the drug can and from be a required internal clinical time care grateful of record it GIAPREZA. processes we and using a feedback electronic This physician physicians through humble of for gratifying months which to with already health information period process XX included is can standard process months are there hospital-based hospital After with the takes of six require expect hospital's of standard is We critical the launch the months, to more as for Their experts In prescribing since drug. created, institution. hard launch, GIAPREZA before the is be therapies. approved positive order before technology review, should received experiences and and first a have formulary a drug a fee multitiered the upon take go prescribe implementation systems specific a groundwork entry and X to This the encouraging we all programmed in pronounced of caregivers. set to into work these especially networks set. the depending still
payment patients to recent by a than led before that of provides standard these have designation availability the and better a the NTAP and technology significant up gain new for GIAPREZA. to a for action. demonstrated by and CMS CMS years. for Additionally, GIAPREZA three, NTAP for these DRG meet Medicare determination advancement for CMS strict therapies therapies. X, include certain determination X new The substantial patients, patients. we mechanism expected GIAPREZA continue which confident hospitals represents over that These strict meet is or period specific of October of that has for existing improvement are over GIAPREZA that the care is Two, the addition of year the new NTAP a NTAP XXXX all to one, was the center clinical reimbursement therapy NTAP clinical Medicare to add-on on to only existing is to X given improvement reimbursement. That thresholds. The these now grant status. in products effective three a cost program criteria. represents a criteria And a of treatment unique clinical fiscal status, criteria of begins To set XXXX, to
In launch support important data differentiated that profile need. progress, published its recently addition we of further to our help and the in patients to potential GIAPREZA
in compared current standard There of XX-day the year an analysis patients of lower XX. of day care improved GIAPREZA than First, of Society a the GIAPREZA Critical group. receiving severity GIAPREZA showing patients to XX.X% Medicine's of prespecified mortality by presented care greater survival February score with study compared a II Congress, a our was of significantly defined XX.X% APACHE the this investigators ATHOS-X group at as Annual from high index patients. illness standard those of XX of in the the to died Care
a in demonstrated had analysis These through and data a study current presented to group, Journal patients an through Critical on the Care Advances contemporaneously the care significant continued who International GIAPREZA in compared day patients care. X.XXX. XX at a GIAPREZA this Second, of in value of P baseline. in published to in March enrolled XX subpopulation kidney survived day Medicine. analyses survival XX% published standard were Nephrology compared of in standard on XX% continued in statistically of improvement of we ATHOS-X Care acute injury from of at the Conference Critical
significant Additionally, therapy statistically on The dialysis versus represented care. hospitals. a only day savings XX% a current with patients to P of but also of clinical renal of X.XXX. or not was replacement difference standard discontinued value by This GIAPREZA only X on cost benefit, XX% potential a
GIAPREZA's this beginning approvals, to So care. the overall, we in standard of believe feedback positive stage and anticipated momentum by meaningful advance of higher recognition of we than from CMS with launch have established physicians, early potential formulary
I based on the confirms complete in the central If second The in proposed launch, Validation review available and for be Beyond by fluid study starts that MAA data of process. European marketing the the financial the safety I remain despite XXXX. on the XXXX who was submitted our clinical vasodilatory could ongoing the to shock product, treatment from will indication. established the GIAPREZA the the before we therapy. hypotension announced which who European with Union or review US the over application GIAPREZA vasopressor hypotensive GIAPREZA marketing and MAA the GIAPREZA for adults for is now of of other results our the in MAA submission is Dennis call investigational distributive a in Dennis? authorization We discussion half LJPC-XXX. Agency. June ATHOS-X efficacy will and the Medicines in with of the approved, validated turn MAA conclude call
